Information Provided By: 
Fly News Breaks for March 9, 2018
CHRS
Mar 9, 2018 | 08:04 EDT
Maxim analyst Jason McCarthy lowered his price target on Coherus Biosciences to $15 after the company's Q4 results, saying its latest cash position suggests operating funding into Q4 of 2018. McCarthy states that $75M in funding from Temasek also depends on whether CHS-1701 gains approval later this year, and the company may require a capital raise in the event of an adverse scenario. The analyst keeps his Buy rating on Coherus Biosciences.
News For CHRS From the Last 2 Days
There are no results for your query CHRS
